VYGR Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. (VYGR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $53.8K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO | Sell | 11,511 | $3.87 | $44.5K | 472,549 −2.4% of holding | |
| Sandrock Alfred | President and CEO | Sell | 14,197 | $3.79 | $53.8K | 484,060 −2.8% of holding | |
| Swartz Robin | COO & CBO | Sell | 6,458 | $3.77 | $24.3K | 199,738 −3.1% of holding | |
| Jorgensen Nathan D. | Chief Financial Officer | Sell | 4,668 | $3.77 | $17.6K | 151,416 −3% of holding | |
| Carter Todd Alfred | Chief Scientific Officer | Sell | 4,174 | $3.76 | $15.7K | 145,718 −2.8% of holding | |
| Sandrock Alfred | President and CEO | Sell | 11,732 | $3.41 | $40.0K | 498,257 −2.3% of holding | |
| Swartz Robin | COO & CBO | Sell | 3,882 | $3.44 | $13.4K | 206,196 −1.8% of holding | |
| Carter Todd Alfred | Chief Scientific Officer | Sell | 3,301 | $3.44 | $11.4K | 149,892 −2.2% of holding | |
| Sandrock Alfred | President and CEO | Sell | 12,192 | $3.78 | $46.1K | 509,989 −2.3% of holding | |
| Swartz Robin | COO & CBO | Sell | 4,569 | $3.85 | $17.6K | 210,078 −2.1% of holding | |
| Carter Todd Alfred | Chief Scientific Officer | Sell | 3,525 | $3.85 | $13.6K | 153,193 −2.2% of holding | |
| Jorgensen Nathan D. | Chief Financial Officer | Sell | 7,666 | $4.78 | $36.6K | 123,834 −5.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.